have uncovered hundreds of loci mediating risk 1,2 . These associations are preferen-14 tially located in non-coding DNA regions 3,4 and in particular to tissue-specific DNase
regulatory sequences that mediate risk, and the genes they affect.
2
We have therefore developed a systematic approach to identify regulatory regions mediating 3 disease risk, and thus generate testable mechanistic hypotheses of the molecular changes that drive 4 disease risk (Supplementary Figure 1) . For each association, we first calculate posterior probabilities 5 of association from GWAS data and thence the set of markers forming the 99% credible interval 6 (CI) 13, 32, 14 . We then overlap CI SNPs with DHS in the region to identify which regulatory regions 7 may harbor risk, and from these SNPs calculate the fraction of posterior probability attributable to 8 each DHS. We chose DHS as they are general markers of chromatin accessibility and typically only 9 150-250 base pairs long, compared to other histone modifications which can span tens to hundreds 10 of kilobasepairs. Next, we identify genes controlled by each DHS by correlating chromatin accessi-11 bility state to expression levels of nearby genes. We use the atlas of tissues available at Roadmap
12
Epigenomics Project (REP) data 15, 16 , where both DHS and gene expression have been measured 13 in the same samples. Finally, we combine the posterior probability of disease association of each 14 DHS and the correlation between that DHS and the expression levels of nearby genes to calculate 15 a per-gene posterior probability of disease association. This allows us to estimate the probability 16 that a gene mediates disease risk, and to rank genes in a locus by these values.
18
DHS peaks, as all epigenetic marks, are called in each sample separately 17 . We therefore clus- 19 tered DHS peaks to identify those corresponding to the same underlying regulatory site, so we could 20 correlate accessibility state of the same site to gene expression data (Supplementary Figure 2) . In 21 56 REP tissues with at least two replicate DHS sequencing runs, we called 22,060,505 narrow-22 sense 150bp peaks at a false discovery rate FDR < 1%, which fell into 1,994,675 DHS clusters of 23 250-400bp each, covering 14.8% of the autosomal genome. Of these, 1,079,138 (54.1%) covering 24 8.5% of the genome passed nominal significance in a statistical replication test (χ 2 1 test, p < 0.05).
25
This subset explains essentially all the heritability attributable to all peaks in multiple sclerosis and transcript levels. We therefore restricted our present analysis to 1, 079, 138 DHS clusters and 30 13771 genes across these 22 REP tissues, though we note our framework can be used with any 31 regulatory feature and expression dataset, and is publicly available.
33
With this framework, we dissected 301 genome-wide significant associations to one of nine AID, 34 using publicly available summary association statistics from samples genotyped on the Immunochip, 35 a targeted genotyping array 18, 19 (available at immunobase.org; Table 1 ). We first collated all re-36 ported genome-wide significant associations reported for each disease, then restricted our analysis 37 to the loci genotyped at high density on the Immunochip 13, 32 . We excluded the Major Histocom-38 patibility Locus, where complex LD patterns make credible interval mapping challenging 20 . For 39 each association, we calculated posterior probabilities of association for all markers and defined 40 credible interval SNP sets 13, 14 . We find a median of 4 (standard deviation, sd = 7.8) DHS clusters 41 overlap CI SNPs, out of a median 822 (sd = 205.2) DHS clusters in each 2Mb window around an izes to DHS clusters: over 25% of the posterior is located on DHS clusters in 132/301 (44%) of loci, 1 and over 50% of the posterior in 53/301 loci (18%) ( Figure 1C ). We reasoned that if DHS clusters 2 harboring CI SNPs actually mediate risk, their accessibility state should be perturbed by the vari-3 ants they harbor, and they should be accessible in disease-relevant cell populations. We find that 4 CI SNPs on DHS clusters are more likely to induce allele-specific accessibility 22 (Fisher exact test 5 p = 7e −6 , Figure 1E ), and that these DHS clusters are more likely to be accessible in immune cell 6 subpopulations ( Figure 1F ). These results show our approach identifies disease-relevant regulatory 7 events, and support the view that common genetic variants influence disease risk by altering the 8 accessibility of gene regulatory regions.
10
Having validated that our analysis was identifying genuine regulatory risk effects, we next turned 11 to identifying specific disease-mediating DHS clusters and the genes they control (Supplementary 12   Table 1 and Supplementary Table 2 ). We focused on the 132 loci where regulatory potential ρ > 0.25, 13 as these associations may be mediated by genetic perturbation of a regulatory region. We found 14 that an average of two DHS clusters (sd = 4.0) account for > 90% of the total association posterior 15 attributable to all DHS clusters in these loci, indicating we can resolve most loci to a small number (88%) of these cases, suggesting that risk-relevant regulatory regions exerting influence over genes 22 at considerable distances ( Table 2 ). The DHS clusters with high ρ values are more likely to be 23 marked as active enhancers of transcription, which can bind distant promoters through long-range
24
DNA looping events 23, 24, 25 , further supporting this conclusion (Supplementary Figure 5) .
26
In several cases, we found evidence supporting a previous hypothesis for a causal gene in a 27 locus. For example, we were able to resolve an association to multiple sclerosis (MS) risk on chro-28 mosome 1 to two DHS clusters, both of which implicate the CD58 gene (γ = 0.49, Figure 2 ).
29
CD58 encodes lymophocyte-function associated antigen 3 (LFA3), a co-stimulatory molecule ex- show association to a region of chromosome 6, with the most significant SNPs residing in the coding 4 region of BACH2. We are able to prioritize the associations for autoimmune thyroid disease (AITD),
5
MS and type I diabetes (T1D) to a single DHS cluster each, and independently prioritize MDN1 as 6 the most likely target gene for these effects (γ AIT D = 0.81, γ M S = 0.42, and γ T 1D = 0.73, Figure 3 ).
7
Our model only attributes a small proportion of the overall posterior probability of association to 8 BACH2 for these diseases (γ AIT D = 0.14, γ M S = 0.09, and γ T 1D = 0.13). In contrast, we find that 9 the associations for IBD and celiac disease (CEL) each identify different DHS clusters and prioritize
10
MAP3K7 (γ IBD = 0.59) and GABBR2 (γ CEL = 0.13), respectively, despite the credible intervals 11 for these diseases essentially overlapping those for AITD, MS and T1D (Figure 3 ). We note that the 12 most associated SNPs for MS, AITD, and T1D are the same (rs72928038), and the R 2 between this
13
SNP and the most associated SNPs of IBD (rs1847472) and CEL (rs7753008) are 0.34 and 0.25,
14
respectively. Similarly, we identify the same DHS cluster and prioritize CTLA4 (γ AIT D = 0.47,
15
γ RA = 0.38, and γ T 1D = 0.52) and ICOS (γ AIT D = 0.41, γ RA = 0.33, and γ T 1D = 0.46) for AITD,
16
RA and T1D associations on chromosome 2 (Supplementary Figure 9) . We are thus able to begin 17 resolving associations across multiple diseases into shared and distinct effects in the same locus.
19
To more generally assess how our approach resolves shared associations, we assessed the overlap 20 between shared signals in the 24 loci. We compared the overlap between 51 pairs of associations in
21
terms of most associated markers, credible interval sets, DHS clusters harboring CI variants, and 22 genes identified (Table 3) . We found that, whilst the overlap between lead variants was low, we ation, shared effects can clearly be identified by considering the likely functional effects in a locus.
28
These observations hold true when we only consider the 17 loci harboring two disease associations 29 (Supplementary Table 3 dividual genes at a distance through DNA looping events mediated by DNA-protein interactions 31 .
42
These competing explanations make different predictions: the former implies many genes will be 43 controlled by the risk-mediating regulator, whereas the latter predicts a limited number of targets.
44
As we are able to prioritize a single gene in the majority of cases, our results strongly suggest that 45 risk is mediated by changes to specific gene regulatory programs affecting particular genes, which 46 must be involved in pathogenesis.
48
More broadly, the observation that most common, complex disease risk aggregates in gene regu- with the smallest Jaccard distance between their DHS peaks positions on the genome.
23
To identify corresponding DHS across samples, we calculated the overlap between neighboring 24 peaks across the 112 replicate samples as:
where, O i,j is the number of base pairs shared by DHS i and j, and l i and l j are the length of DHS 26 i and j respectively. We then grouped DHS with a graph-based approach, the Markov Clustering 
where n 1 is the number of cell types where DHS cluster d is active in both replicates; n 2 is the 36 number of cell types where the cluster is active in only one of the two replicates; and n 3 is the 37 number of cell types where the cluster is inactive in both replicates. For N = 56 tissues in our data test. We used a permutation-based approach to assess the significance of the correlation between
21
DHS clusters and gene expression using a random set of 2000 genes from across the genome. We 
25
We next calculated the proportion of posterior probability of association transmitted from DHS
where χ 2
is the chi-squared test statistic corresponding to the empirical correlation P value for
28
DHS cluster d and gene g i . From this we computed the total posterior transmitted from DHS cluster
For each gene, we then sum over all DHS clusters D to obtain the overall posterior probability of 31 association:
In practice, if P d,g > 0.25 we set β d,g to zero to control noise from small values (Supplementary 33 Figure 13 ) SNPs from all diseases as a joint set. We found this enrichment to be consistent across minor allele 6 frequency bins (Supplementary Figure 14) . 
12
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